J&J’s Tecvayli/Darzalex nod is the second under a new priority voucher scheme.
ApexOnco Front Page
Recent articles
Rinzimetostat efficacy wanes further as the company moves into phase 3.
The company takes a PD-L1 x VEGF asset into phase 3.
A new phase 3, Manifest-3, will start in April to support US filing.
New first-in-human study initiations feature yet more in vivo Car assets.
Intismeran autogene’s Interpath-001 trial reads out this year.
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
Armed with $75m the company takes a risky asset into the clinic.
